Role of the novel endoribonuclease SLFN14 and its disease causing mutations in ribosomal degradation by Morgan, Neil et al.
 
 
University of Birmingham
Role of the novel endoribonuclease SLFN14 and its
disease causing mutations in ribosomal
degradation
Morgan, Neil; Fletcher, Sarah; Khan, Abdullah; Pisarev, Andrey; Pisareva, Vera;
Tcherepanov, Andrew
DOI:
10.1261/rna.066415.118
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Morgan, N, Fletcher, S, Khan, A, Pisarev, A, Pisareva, V & Tcherepanov, A 2018, 'Role of the novel
endoribonuclease SLFN14 and its disease causing mutations in ribosomal degradation', RNA, vol. 24, no. 7, pp.
939-949. https://doi.org/10.1261/rna.066415.118
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Role of the novel endoribonuclease SLFN14 and its
disease-causing mutations in ribosomal degradation
SARAH J. FLETCHER,1,4 VERA P. PISAREVA,2,4 ABDULLAH O. KHAN,1 ANDREW TCHEREPANOV,3
NEIL V. MORGAN,1 and ANDREY V. PISAREV2
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom
2Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
3Department of Physiology and Pharmacology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
ABSTRACT
Platelets are anucleate and mostly ribosome-free cells within the bloodstream, derived from megakaryocytes within bone marrow
and crucial for cessation of bleeding at sites of injury. Inherited thrombocytopenias are a group of disorders characterized by a low
platelet count and are frequently associated with excessive bleeding. SLFN14 is one of the most recently discovered genes linked to
inherited thrombocytopenia where several heterozygous missense mutations in SLFN14 were identified to cause defective
megakaryocyte maturation and platelet dysfunction. Yet, SLFN14 was recently described as a ribosome-associated protein
resulting in rRNA and ribosome-bound mRNA degradation in rabbit reticulocytes. To unveil the cellular function of SLFN14
and the link between SLFN14 and thrombocytopenia, we examined SLFN14 (WT/mutants) in in vitro models. Here, we show
that all SLFN14 variants colocalize with ribosomes and mediate rRNA endonucleolytic degradation. Compared to SLFN14 WT,
expression of mutants is dramatically reduced as a result of post-translational degradation due to partial misfolding of the
protein. Moreover, all SLFN14 variants tend to form oligomers. These findings could explain the dominant negative effect of
heterozygous mutation on SLFN14 expression in patients’ platelets. Overall, we suggest that SLFN14 could be involved in
ribosome degradation during platelet formation and maturation.
Keywords: endoribonuclease; platelet; ribonuclease; RNA degradation; SLFN14; thrombocytopenia
INTRODUCTION
Inherited thrombocytopenias (ITs) are a group of disorders
determined by a relative decrease of platelet count resulting
from genetic heterogeneity (Nurden and Nurden 2007).
ITs are usually asymptomatic, but some individualsmay expe-
rience excessive bleeding ranging frommild to severe. Over 30
genes are shown to be involved in ITs (Favier and Raslova
2015; Levin et al. 2015; Johnson et al. 2016a,b; Pecci 2016).
One of these, SLFN14, was discovered only very recently
where Fletcher et al. (2015) identified three heterozygousmis-
sense mutations in affected family members from three unre-
lated families, predicted to encode substitutions K218E,
K219N, and V220D within an AAA domain of SLFN14.
Patients revealed moderate IT with severe bleeding history
and platelet ATP secretion defects. Importantly, SLFN14 ex-
pression is dramatically reduced in patients’ platelets (up to
80%) compared to healthy controls and in transfected cells
(up to 95%), suggesting a dominant negative effect ofmutants
on the synthesis or stability of the wild-type (WT) form
(Fletcher et al. 2015). Shortly after this seminal study,
Marconi et al. (2016) reported the fourth heterozygous mis-
sensemutation in SLFN14 associated with IT. Notably, the af-
fected residue R223W in the AAA domain of SLFN14 is
located nearby to previously reported mutations. This novel
mutation was shown to mediate reduced proplatelet forma-
tion and decreased megakaryocyte maturation in patient de-
rived megakaryocytes. Consistent with above mentioned
data, SLFN14 expressionwas below 50%despite the heterozy-
gous nature of the mutation (Marconi et al. 2016). This find-
ing supports the idea of dominant negative effect of mutant
forms on the SLFN14 WT expression (Fletcher et al. 2015;
Marconi et al. 2016). However, due to the limited knowledge
of the function of SLFN14, more detailed characterization
of SLFN14 and its role in platelet biogenesis is critically
important.
Alongside these genetic studies, Pisareva et al. (2015) dem-
onstrated the endoribonucleolytic activity of purified
SLFN14 in biochemical experiments and suggested the role
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of this protein in translation control. More specifically, it was
shown that SLFN14 associates with ribosomes and ribo-
somal subunits, and cleaves RNA, but preferably rRNA and
ribosome-bound mRNA, in a Mg2+-dependent and NTP-in-
dependent manner. This leads to the degradation of ribo-
somal subunits (Pisareva et al. 2015). More recently a more
global approach (Mills et al. 2016) described a study of a ri-
bosomal rescue pathway which involves both erythroid cells
and platelets and the many proteins involved in this process
such as proteins like SLFN14.
Based on the presence of characteristic slfn signature mo-
tifs, SLFN14 belongs to the Schlafen protein family, limited to
mammals and encoded by six SLFN genes in humans
(Geserick et al. 2004; Brady et al. 2005). All family members
comprise a conserved amino terminus containing a putative
AAA domain implicated in ATP binding, but only longer
forms of SLFN genes (including SLFN14) possess a car-
boxy-terminal extension with motifs, which are specific for
superfamily I DNA/RNA helicases (Geserick et al. 2004).
SLFN proteins are involved in T-cell development (Schwarz
et al. 1998; Geserick et al. 2004; Berger et al. 2010), differen-
tiation (Patel et al. 2009), and immune response (Li et al.
2012), but their exact cellular functions still remain elusive.
To get insights into the fundamental role of SLFN14, we
aimed to assay endoribonuclease activity, intracellular distri-
bution, and stability ofWT and IT-related missense mutation
forms of protein in human cells. We found that SLFN14
colocalizes with ribosomes and causes the endoribonucleo-
lytic degradation of rRNA in cells. Mutations do not affect
all tested activities of the protein, but dramatically reduce
mutants’ stability at post-translational level and down-regu-
late the coexpression of WT form. In light of our data, impli-
cations for the fundamental role of SLFN14 are discussed.
RESULTS
SLFN14 WT and IT-related missense mutation variants
reveal the same subcellular distribution, colocalize
with 5.8S rRNA, and cause ribosome degradation
in Dami cells
To date, data on SLFN14 activity are limited by describing the
protein as an endoribonuclease in a rabbit reticulocyte lysate
and in a reconstituted in vitro mammalian translation system
(Pisareva et al. 2015). To expand our knowledge on the func-
tion of this protein, we aimed to analyze SLFN14 in transfect-
ed cell lines. Therefore, we used myc-tagged human SLFN14
WT (SLFN14(WT)-myc) and three previously reported
missense mutation variants K218E, K219N, and V220D
(SLFN14(K218E)-myc, SLFN14(K219N)-myc, and SLFN14
(V220D)-myc, respectively) that were cloned into the mam-
malian expression vector for transient expression (Fletcher
et al. 2015). Dami cells, a human megakaryocytic leukemia
cell line, were selected as a host cell line. Dami cells were
differentiated into megakaryocyte like cells using Phorbol
12-myristate 13-acetate (PMA) then transiently transfected
with SLFN14 (WT/mut)-myc constructs for 48 h and were
subsequently analyzed by immunostaining. Expression of
SLFN14 (WT)-myc revealed a diffuse cytoplasmic and nucle-
ar localization with some punctate structures observed (Fig.
1A). None of the mutations affected the subcellular distribu-
tion and staining pattern of the protein (Fig. 1A,B). Such a
pattern may indicate the colocalization of SLFN14 with
A
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FIGURE 1. Significant colocalization is observed between SLFN14
(WT/mut)-myc and 5.8S rRNA in differentiated Dami cells. There is
no alteration in subcellular distribution between SLFN14 (WT)-myc
and SLFN14 (mut)-myc distribution or colocalization with 5.8S
rRNA. (A) Transiently transfected differentiated Dami cells expressing
SLFN14(WT/mut)-myc for 48 h were probed with rabbit anti-myc
and mouse anti-5.8S primary antibodies followed by incubation with
anti-rabbit AlexaFluor488, anti-mouse AlexaFluor568 secondary anti-
bodies and TO-PRO-3 Iodide nuclear stain. A representative image is
shown from three independent experiments, scale bar denotes 15 µm.
(B) Pearson’s correlation coefficient data demonstrating no change in
colocalization or subcellular-distribution between 5.8S rRNA and
SLFN14 (WT)-myc or SLFN14 (mut)-myc in comparison to control ar-
eas. n = at least 40 cells analyzed from three independent experiments.
(C) Pearson’s correlation coefficient data demonstrating a significant in-
crease in colocalization between 5.8S rRNA and SLFN14 (WT/mut)-myc
staining in comparison to control areas. (∗∗∗) P≤ 0.001 colocalization
between 5.8S rRNA and SLFN14 (WT/mut)-myc and control area.
Error bars ± SD.
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nonuniform dispersed components of the cell. It was previ-
ously shown that SLFN14 strongly binds to purified ribo-
somes in the sucrose density gradient (SDG) centrifugation
experiment (Pisareva et al. 2015). Therefore, we suggested
that ribosomes could be a binding partner for SLFN14 in
the cell. Immunostaining experiments with the antibodies
against 5.8S rRNA revealed that SLFN14 (WT)-myc signifi-
cantly colocalizes with ribosomes, and the presence of muta-
tions do not influence this colocalization (Fig. 1A–C).
SLFN14 was reported to possess the ribosomal binding site
within 179 amino acids in the central part of the protein be-
side the AAA domain to the carboxyl terminus (Pisareva et al.
2015). Therefore, we proposed that SLFN14 should bind
directly to the ribosomes in cells.
Rabbit SLFN14 was previously shown to cause rRNA
cleavage and ribosome degradation in a rabbit reticulocyte ly-
sate and in a reconstituted in vitro mammalian translation
system (Pisareva et al. 2015). Notably, SLFN14 is highly ho-
mologous among all mammalian species. To test whether
SLFN14 could provide ribosome degradation in the intact
cells of human origin, we estimated 5.8S rRNA content
in transiently transfected Dami cells expressing SLFN14
(WT/mut)-myc for 48 h by immunostaining of 5.8S rRNA.
For all SLFN14 variants, we detected ∼50% to 70% statisti-
cally significant reduction of 5.8S rRNA content (Fig. 2).
Based on staining intensity values (Fig. 2B), we cannot state
that mutations compromise the ribosome degradation activ-
ity of SLFN14. However, taking into account previous bio-
chemical data (Pisareva et al. 2015), we suggest the more
direct rather than auxiliary role of SLFN14 in the ribosome
degradation.
In conclusion, SLFN14 binds to the ribosomes mediating
ribosome degradation in megakaryocyte-like cells, and IT-re-
lated missense mutations do not compromise these cellular
activities of protein assuming that SLFN14 dysfunction takes
place at a different molecular level.
Overexpressed SLFN14 WT and mutants associate
with ribosomes and individual ribosomal subunits
causing the endoribonucleolytic cleavage of rRNA
in HEK293T cells
To evaluate whether the discovered SLFN14 activities are re-
lated to a megakaryocyte-specific cell line, we also assayed the
protein in HEK293T cells, a human embryonic kidney cell
line. To analyze the ribosomal binding of SLFN14, transiently
transfected HEK293T cells expressing SLFN14(WT/mut)-
myc or harbouring empty vector (EV) for 48 h were collected
and lysed, and cell lysates were subjected to SDG centrifuga-
tion in order to obtain 80S-, 60S-, and 40S-containing frac-
tions. Notably, we did not observe the significant difference
in polysome profiles upon SLFN14(WT/mutants) expression
compared to EV control. All SLFN14 forms except SLFN14
(K218E)-myc bind predominantly to 80S ribosomes and
60S ribosomal subunits (Fig. 3A). The weak signals of
SLFN14 (K219N)-myc and the absence of SLFN14
(K218E)-myc in ribosomal peaks correlate with the low ex-
pression level of proteins (Fig. 3B). It was previously shown
that the expression level of SLFN14 (K218E)-myc in
B
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FIGURE 2. Reduced intensity of 5.8S rRNA staining in differentiated
Dami cells expressing wild-type/mutant SLFN14 constructs. (A)
Transiently transfected Dami cells expressing SLFN14(WT/mut)-myc
for 48 h were probed with rabbit anti-myc and mouse anti-5.8S primary
antibodies followed by incubation with anti-rabbit AlexaFluor488 and
anti-mouse AlexaFluor568 secondary antibodies, respectively. The
dashed white line outlines cells expressing SLFN14 (WT/mut)-myc,
the solid line represents the outline of cells which were not transfected.
A representative image is shown from three independent experiments.
Scale bar denotes 15 µm. (B) Average intensity measurements from the
entire cell area were quantified from images represented in A. n = at least
40 cells analyzed from three independent experiments. (∗∗∗) P≤ 0.001
when compared to nontransfected cells. Error bars ± SD.
Cellular analysis of the ribonuclease SLFN14
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FIGURE 3. Association of SLFN14 (WT/mut)-myc with ribosomes and ribosomal subunits resulting in rRNA endonucleolytic degradation in
HEK293T cells. (A) Binding of SLFN14 (WT/mut)-myc to 80S monosomes, 60S, and 40S ribosomal subunits obtained after SDG centrifugation
of HEK293T cell lysates with overexpressed one of SLFN14 (WT/mut)-myc forms. Assignment of 80S monosomes, 40S, and 60S subunits in gradient
fractions was based on immunoblotting with anti-RPS19 and anti-RPL3 antibodies as exemplified by the EV control. Ribosomal fractions were con-
centrated and analyzed by immunoblotting with anti-SLFN14 antibodies. (B) Expression levels of SLFN14 (WT/mut)-myc in HEK293T cells assayed
by immunoblotting with anti-SLFN14 and anti-GAPDH (control) antibodies. (C) Binding of recombinant SLFN14 (WT)-65 kDa and SLFN14
(K218E)-65 kDa to assembled 80S ribosomes assayed by SDG centrifugation and Coomassie staining. (D) rRNA degradation in SLFN14
(WT/mut)-overexpressed HEK293T cells assayed by denaturing agarose/formaldehyde gel electrophoresis (n = 3 independent experiments). The as-
terisks indicate the main bands of rRNA fragments. Positions of the 28S rRNA and 18S rRNA are shown. (E) Integrity analysis of rRNA. (Left panel)
Representative electrophoretic profiles of total RNA obtained using the Agilent 2200 TapeStation system from SLFN14(WT/mut)-overexpressed
HEK293T cells. Arrows indicate the appearance of rRNA degradation fragments. (Right panel) representative data output gel-like images. The average
RIN scores from three independent experiments are shown.
Fletcher et al.
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HEK293T cells is the lowest among all the described mutants
(Fletcher et al. 2015). Therefore, we hypothesized that the
absence of SLFN14 (K218E)-myc in ribosomal fractions is
a result of the low content and/or continuous degradation
during cell lysate manipulation rather than of the compro-
mised ribosomal binding activity. To test our hypothesis,
we utilized a previously described Escherichia coli expression
vector for a 65 kDa carboxy-terminally truncated His-tagged
form of human SLFN14 (SLFN14-65 kDa) (Pisareva et al.
2015). This was the longest form of SLFN14, which was avail-
able in a soluble state after expression, whereas all longer
forms completely precipitated (Pisareva et al. 2015). We
introduced the corresponding mutation into SLFN14-65
kDa to obtain K218E mutant expression vector [SLFN14
(K218E)-65 kDa]. Due to limited solubility, SLFN14-65
kDa or SLFN14 (K218E)-65 kDa proteins in the form of el-
uates after Ni-NTA resin were mixed with 80S ribosomes re-
constituted from purified 40S and 60S ribosomal subunits.
The reaction mixture was subjected to the centrifugation
through SDG to separate 80S ribosomes from unbound com-
ponents, and the 80S ribosomal peak was assayed by dena-
tured PAGE and Coomassie staining. Both SLFN14-65 kDa
and SLFN14 (K218E)-65 kDa were found associated with
80S ribosomes (Fig. 3C). Therefore, none of the SLFN14 mu-
tations affect the ribosomal binding activity of SLFN14 in dif-
ferent cell lines.
In the immunostaining experiment, all SLFN14 forms re-
duced the intensity of 5.8S rRNA staining in Dami transfect-
ed cells that could be a result of ribosome degradation. In our
next experiment, we raised several key questions. Could the
rRNA degradation process be involved in the elimination of
ribosomes? Is the degradation activity of SLFN14 cell type-
specific? How does the rRNA pattern look after the overex-
pression of SLFN14? To answer these questions, transiently
transfected HEK293T cells expressing SLFN14(WT/mut)-
myc or harbouring EV for 24 h were collected, total RNA
was isolated, and the equal amounts of total RNA from
each sample were assayed by denaturing agarose/formalde-
hyde gel electrophoresis. In contrast to EV, overexpression
of any SLFN14 form resulted in the characteristic pattern
of rRNA endoribonuclealytic degradation (Fig. 3D).
To support our data, we analyzed RNA samples derived
from either nontransfected HEK293T cells or cells transfect-
ed with the empty myc-vector/SLFN14(WT/Mut)-myc for
the RNA integrity using the Agilent 2200 TapeStation sys-
tem. The Agilent system generates an electropherogram
profile, gel-like image, and RNA integrity number (RIN)
providing the information about RNA quality. Our study
demonstrates excellent RIN scores for nontransfected and
EV-transfected samples, and lower RIN scores, reflecting
partial degradation of rRNA, for SLFN14(WT/Mut)-trans-
fected samples (Fig. 3E) indicating RNA degradation seen
in Figure 3D is due to the activity of SLFN14(WT/Mut)
overexpression. In summary, the endoribonucleolytic activi-
ty of SLFN14 should relate to the observed ribosome degra-
dation in transfected cells. Notably, IT-related missense
mutations do not affect rRNA cleavage pattern pointing to
that SLFN14 dysfunction in platelet biogenesis cannot be
explained by the compromised endoribonucleolytic activity
of protein.
SLFN14missense mutations cause the low expression of
mutants as a result of post-translational degradation due
to partial misfolding and implicate SLFN14 WT into the
degradation through the formation of oligomeric forms
One of the interesting reported findings is that SLFN14-relat-
ed IT patients displayed 65%–80% reduction in SLFN14 pro-
tein level despite the heterozygosity, assuming that themutant
allele influences the synthesis and/or stability of both mutant
and WT proteins (Fletcher et al. 2015; Marconi et al. 2016).
This effect was confirmed in overexpression studies in trans-
fected cells (Fletcher et al. 2015). Therefore, in our next set of
experiments, we aimed to determine the stage, at which mu-
tant expression could be affected, and to understand howmu-
tants could influence the SLFN14 WT protein level. For that,
we used above mentioned SLFN14 (WT/mut)-myc vectors
and a newly constructed SLFN14 (WT)-GFP mammalian ex-
pression vector containing the human SLFN14 coding region
with a GFP tag. Transiently transfected HEK293T cells coex-
pressing SLFN14 (WT)-GFP and either the SLFN14
(WT/mut)-myc vectors for 48 h were analyzed by immuno-
blotting. First, consistently with published data (Fletcher
et al. 2015), we found that SLFN14 (K218E)-myc, SLFN14
(K219N)-myc, and SLFN14 (V220D)-myc expression was re-
duced to 10%, 10%, and 54% of SLFN14(WT)-myc expres-
sion, respectively (Fig. 4A,B). Second, SLFN14(WT)-GFP
protein level dropped to 37% and 54% upon coexpression
of that with SLFN14(K218E)-myc and SLFN14(K219N)-
myc, respectively, compared to coexpression with SLFN14
(WT)-myc control (Fig. 4A,B). These data correlate with
the proposed dominant negative effect of SLFN14 mutants.
The detected elevation of SLFN14 (WT)-GFP protein level
upon coexpression with SLFN14 (V220D)-myc compared
to that with the SLFN14 (WT)-myc control was not statisti-
cally significant and we therefore suggest that this mutant be-
haves in a different way (Fig. 4A,B).
The regulation of expression of SLFN14 mutants should
take place at either the transcriptional or post-translational
level. To evaluate the effect of mutations on the RNA level,
we used qRT-PCR. We isolated total RNA from HEK293T
cells expressing one of SLFN14 (WT/mut)-myc variants,
and assayed samples for expression of SLFN14 and GAPDH
control transcripts. The difference in a normalized transcript
concentration between SLFN14 WT and each mutant form
did not exceed 1.6-fold (Fig. 4C). Importantly, the endoge-
nous SLFN14 transcript was not detected (Fig. 4C). Taking
into account a strong reduction of SLFN14 (K218E)-myc
and SLFN14 (K219N)-myc expression, we conclude that
the regulation of expression should occur at a post-
Cellular analysis of the ribonuclease SLFN14
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FIGURE 4. Role of SLFN14 missense mutations in protein expression. (A) Immunoblotting image showing levels of SLFN14 (WT/mut)-myc and
SLFN14 (WT)-GFP in HEK293T cells transiently expressing the above constructs. The blot was probed with anti-SLFN14 and anti-GAPDH primary
antibodies followed by incubation with anti-rabbit HRP. (B) Quantification of SLFN14 (WT/mut)-myc and SLFN14 (WT)-GFP protein expression
from immunoblotting analysis of n = 3 lysate samples per condition from three independent experiments. All values are mean ± SD. (C)
Quantification of relative SLFN14 (WT/mut)-myc transcript level normalized to GAPDH control transcript from qRT-PCR test data on n = 6 inde-
pendent sets of lysate samples. All values are mean ± SD. (D) Fluorescence emission spectra of SLFN14 (WT)-45 kDa and SLFN14 (K218E)-45 kDa
proteins collected at the same protein concentration at two different temperatures: 25°C and 65°C (n = 3 independent experiments). (E)
Coimmunoprecipitation (co-IP) analysis in HEK293T cells to assess both wild-type and mutant GFP labeled SLFN14 with SLFN14(WT)-myc to
look at formation of hetero-oligomers between wild-type and mutant SLFN14. (F) Purified recombinant SLFN14-45 kDa WT and mutants resolved
by SDS-PAGE. (G) Oligomerization capacity of SLFN14-45 kDaWT andmutants assayed by native PAGE. Positions of different oligomeric forms are
shown.
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translational rather than a transcriptional stage, at least for
these two mutants. We then hypothesized that missense mu-
tations could affect protein folding. To test this hypothesis,
we compared folding between the SLFN14 WT and K218E
form, which revealed the most dramatic effect on its own ex-
pression and WT form coexpression in our experiments.
Tertiary structure of protein can be analyzed using a fluores-
cence spectroscopy technique based on intrinsic protein fluo-
rescence. Two amino acids, Trp and Tyr, are experimentally
used to obtain a strong fluorescent signal. The emission en-
ergy of these residues is highly sensitive to the polarity of
the environment. In the native folded conformation, Trp
and Tyr are generally hidden in the hydrophobic core of
the protein giving a high intensity fluorescence signal. In
contrast, a hydrophilic environment results in a low intensity
fluorescence signal. The protein sample is excited at 280-
nm wavelength, and fluorescence spectrum is collected in a
300- to 400-nm wavelength range. For the experiment, we
used the already described E. coli expression vector for 45
kDa carboxy-terminally truncated His-tagged form of hu-
man SLFN14 (SLFN14-45 kDa) (Pisareva et al. 2015).
Compared to SLFN14-65 kDa and longer protein forms,
SLFN14-45 kDa could be purified in a large amount with
high homogeneity (Pisareva et al. 2015). We inserted the cor-
responding mutation into SLFN14-45 kDa to obtain K218E
mutant expression vector (SLFN14 (K218E)-45 kDa). Anal-
ysis of SLFN14-45 kDa and SLFN14(K218E)-45 kDa fluores-
cence spectra revealed the difference in the maximum of
emission energy at 340 nm wavelength indicating different
conformations of proteins and confirming our hypothesis
(Fig. 4D). In the control experiment, after incubation of pro-
teins at 65°C resulting in their denaturation, maximum in-
tensities of emission matched (Fig. 4D). In conclusion, we
state that SLFN14 missense mutations lead to post-transla-
tional degradation of mutants as a result of partial protein
misfolding.
Taking into account a post-translational regulation of
SLFN14 expression, we suggested that mutants could involve
WT protein with degradation through the formation of het-
erogeneous oligomeric forms. Indeed, AAA proteins form
oligomeric assemblies, mostly homo-hexamers, which are
critical for their activities (Ogura and Wilkinson 2001). To
evaluate the SLFN14 tendency to oligomerization we
performed coimmunoprecipitation (co-IP) studies and as-
sayed the mobility of protein in native PAGE. For co-IP stud-
ies HEK293T cells coexpressing SLFN14(WT)-myc and
SLFN14(WT/mut)-GFP for 48 h were lysed, SLFN14(WT)-
myc was pulled down using mouse anti-myc antibodies,
and IP lysates were analyzed by immunoblotting. Figure 4E
demonstrates co-IP of both wild-type and mutant GFP la-
beled SLFN14 with SLFN14(WT)-myc suggesting the forma-
tion of hetero-oligomers between wild-type and mutant
SLFN14. Furthermore, we used the above mentioned
SLFN14-45 kDa and SLFN14 (K218E)-45 kDa proteins as
well as newly constructed, E. coli expressed and purified
SLFN14 (K219N)-45 kDa and SLFN14 (V220D)-45 kDamu-
tants (Fig. 4F) to assay the mobility of protein in native
PAGE. As a result, SLFN14 WT migrated in a native PAGE
in the form of homo-oligomers of different orders, and
none of the mutations affected the protein pattern (Fig. 4G).
Therefore, we suggest that our findings underlie the mecha-
nism of SLFN14 expression regulation in transfected cells.
DISCUSSION
SLFN14 is one of the most recently discovered genes known
to cause IT. Four missense mutations of SLFN14 are identi-
fied to date, linked to dysregulated platelet maturation and
platelet dysfunction, resulting in disproportionate bleeding
in affected patients. Schlafen family members are poorly
studied and their functions are not completely understood
making the cellular role of SLFN14 hard to predict. The
only functional characterization report describes SLFN14 as
an endoribonuclease in a rabbit reticulocyte lysate. To ad-
vance our knowledge on SLFN14, we characterized the pro-
tein in different transfected cell lines.
Consistent with published data, we detected a diffuse
immunostaining pattern for overexpressed SLFN14 WT
throughout the nucleus and cytoplasm with some punctate
structures in Dami cells. Immunostaining assay also revealed
that the nonuniform distribution of SLFN14WT is a result of
colocalization with 5.8S rRNA indicating the ribosome as a
binding partner for the protein in the cell. Taking into ac-
count the reported biochemical data, we assayed the rRNA
degradation capacity of protein in question, and found that
SLFN14 WT overexpression leads to rRNA endoribonucleo-
lytic cleavage and degradation in Dami and HEK293T cells,
which represent megakaryocyte-related and unrelated cell
lines, respectively. Therefore, SLFN14 is a bona fide mamma-
lian endoribonuclease. Importantly, only few endoribonu-
cleases have been described so far. That is because it is hard
to predict the endoribonucleolytic activity of protein based
on its primary sequence due to a high variety in the organi-
zation of the active center and, thus, a wide structural diver-
sity of this class of enzymes. Notably, IT-related missense
mutations K218E, K219N, and V220D do not affect the dis-
tribution, 5.8S rRNA colocalization, and endoribonucleolytic
activity of SLFN14 in the cell. This data implies that protein
dysfunction in platelet biogenesis takes place at a different
cellular level.
Here we show that all SLFN14 forms bind to ribosomes in
cells. Notably, as follows from the experiment in the binary
system with the recombinant protein, ribosomal association
of SLFN14 is direct and not mediated by cofactors. This is
the first reported case of direct ribosomal association of
endoribonuclease within the cell.
It was reported that SLFN14missense mutations cause the
decreased protein expression in transfected cells and down-
regulate the expression of SLFN14 WT form in patients.
Consistently, in our study, the protein level dropped
Cellular analysis of the ribonuclease SLFN14
www.rnajournal.org 945
 Cold Spring Harbor Laboratory Press on July 6, 2018 - Published by rnajournal.cshlp.orgDownloaded from 
dramatically for K218E and K219N mutants and moderately
for V220D mutant in HEK293T cells. Moreover, GFP-tagged
SLFN14 (WT) protein levels reduced by 3 and 2 times upon
coexpression with K218E and K219N mutants, respectively,
compared to coexpression with WT control. qRT-PCR data
on the SLFN14 transcript levels displayed that regulation of
expression takes place at a post-translational rather than a
transcriptional stage. We hypothesized that the missense mu-
tations could cause partial misfolding of protein. Indeed, to
prevent the potentially hazardous effect, the cell uses several
degradation pathways to destroy improperly folded pro-
teins (Nedelsky et al. 2008; Smith et al. 2011; Varshavsky
2012). Interestingly, protein misfolding is shown to underlie
hundreds of diseases (Valastyan and Lindquist 2014). Fluo-
rescence spectroscopy demonstrated different tertiary struc-
tures of SLFN14 WT and K218E supporting our suggestion
that post-translational degradation of mutants is a result of
partial protein misfolding. But how do SLFN14 mutants me-
diate SLFN14 WT degradation? All AAA proteins, which
SLFN14 belongs to, tend to form oligomers in the cell. Con-
sistently, co-IP and native PAGE revealed that SLFN14 WT
form complexes with mutant SLFN14, forming oligomers
of different order, and mutations do not affect the protein
pattern in the gel. Therefore, SLFN14 mutants could cause
increased degradation of wild-type SLFN14 by forming het-
ero-oligomers of wild-type/mutant SLFN14 leading to insta-
bility of the entire protein complex, and could explain a
dominant-negative effect of mutant allele on SLFN14WT ex-
pression in patients.
What are the implications of our findings for platelet bio-
genesis and IT-related dysregulation of this process? It is well
known that mature platelet and erythrocytes have only resid-
ual “RNA content” levels, if any (Hamilton 2010; Angénieux
et al. 2016). Here we show that SLFN14 reveals the endoribo-
nucleolytic activity resulting in rRNA cleavage and degrada-
tion in different transfected cells. Therefore, we cautiously
speculate that SLFN14 causes RNA degradation and, in
such a way, mediates RNA clearance during platelet and
erythrocyte maturation. Interestingly, SLFN14 was found
abundant in rabbit reticulocytes, but below the detection lim-
it in rabbit liver, lung, and brain tissues (Pisareva et al. 2015).
Moreover, endogenous SLFN14 expression was shown to be
undetectable or extremely low in HEK293, HEK293T, HeLa,
CEM, and Jurkat cells (Li et al. 2012). On the other hand, in
the independent studies, SLFN14 was demonstrated to be in-
volved in platelet biogenesis. Taking these data together, we
again cautiously hypothesize that SLFN14 is specifically ex-
pressed and acts during these two blood cell types maturation
processes.
Interestingly a recently published and more global ap-
proach (Mills et al. 2016) was studied to outline a ribosomal
rescue pathway which involves both erythroid cells and plate-
lets and the many proteins involved in this process such as
proteins not dissimilar to SLFN14. Therefore, our more spe-
cific study follows on from this and complements this study
by implicating a ribosomal pathway more specifically in
SLFN14 as outlined here.
Sincewedid not detect any difference between SLFN14WT
andmutants in our experiments, except at the expression lev-
el, we think that the dysregulation of thrombopoiesis is a re-
sult of improper degradation of mutants. There are
examples of human genetic diseases caused by the degrada-
tion of mutant proteins despite these proteins retaining their
functionality (Valastyan and Lindquist 2014). A canonical ex-
ample is the disease cystic fibrosis linked to a single phenylal-
anine residue deletion at position 508 of cystic fibrosis
transmembrane conductance regulator protein targeting a
misfolded protein for degradation (Qu et al. 1997). Another
case of improper degradation-associated disease is in Gauch-
er’s disease, which is caused by a variety ofmutations in β-glu-
cosidase (Futerman and van Meer 2004; Cox and Cachón-
González 2012). In conclusion, our findings contribute to
the understanding of the mechanism underlying platelet bio-
genesis in general and SLFN14-related IT more specifically.
MATERIALS AND METHODS
Plasmids
Mammalian expression vector containing the full coding region of
human SLFN14 and GFP-tag was purchased from GeneCopoeia
[SLFN14(WT)-GFP]. Mammalian expression vector for human
SLFN14(WT)-myc as well as E. coli-based expression vectors for
His-tagged carboxy-terminal deletion mutants of human SLFN14
[SLFN14(WT)-65 kDa and SLFN14(WT)-45 kDa] have been previ-
ously described (Fletcher et al. 2015; Pisareva et al. 2015). The
SLFN14 missense mutations K218E, K219N, and V220D were cre-
ated by site-directed mutagenesis of corresponding vectors.
Antibodies
We used myc (Cell Signaling Technology, #9B11), myc (Abcam,
#9106), 5.8S rRNA (Abcam, #ab37144), SLFN14 (Abcam,
#ab106406), RPS19 (Bethyl Laboratories, #A304-002A), RPL3
(Bethyl Laboratories, #A305-007A), GFP (Sigma, #G1544), GAPDH
(Abcam, #ab9485), anti-rabbit AlexoFluor488 (ThermoFisher
Scientific, #A-11034), and anti-mouse AlexoFluor568 (Thermo-
Fisher Scientific, #A-11004) antibodies.
Cell culture, plating, and transfection
HEK293T cells were cultured in DMEM plus L-glutamine
(Invitrogen) (plus 10% fetal calf serum, 1% pen/strep [both from
GIBCO]). Dami cells were cultured in RPMI (GIBCO) plus 1% L-
glutamine, 10% fetal calf serum, and 1% pen/strep. Cells were plated
into six-well plates with/without sterilized 23-mm glass coverslips at
a density of 5 × 105 cells/mL. Dami medium was supplemented with
PMA (Phorbol 12-myristate 13-acetate [Sigma-Aldrich]) to a final
concentration of 10 µM. Cells were transfected 24 h post-plating
with 5.5 µL (1 mg/mL at pH 7.4 PEI [Polyethyleneimine; Sigma-
Aldrich]), 1.2 µg of DNA, and 140 µL of Optimem (Invitrogen)
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per well of a six-well plate and used in studies 24–48 h post-
transfection.
Purification of ribosomal subunits
Native rabbit 40S and 60S subunits were purified as described
(Pisarev et al. 2007).
Purification of E. coli-expressed SLFN14 WT
and mutants
Recombinant SLFN14(WT/mut)-45 kDa were expressed in 1 L of
E. coli BL21(DE3) media after induction with 0.1 mM IPTG for
16 h at 16°C. After expression, the proteins were isolated by affinity
chromatography on Ni-NTA agarose followed by FPLC on aMonoS
column. FPLC fractions were collected across a 100–500 mM KCl
gradient. SLFN14(WT/mut)-45 kDa were eluted in the range of
210–250 mM KCl.
Recombinant SLFN14(WT/K218E)-65 kDa were expressed in 1 L
of E. coli BL21(DE3)media after induction by 0.1 mM IPTG for 16 h
at 16°C and purified on Ni-NTA agarose according to manufactur-
er’s protocol.
HEK293T cell extract preparation
To prepare cell extract, transiently transfected HEK293T cells ex-
pressing SLFN14(WT/mut)-myc or harbouring EV were cultured,
plated and transfected as described previously. Prior to use cells
were washed three times with 1× PBS (pH 7.4). HEK293T cells
(3 × 105 cells) were resuspended in 300 µL of prechilled Tris-based
lysis buffer (20 mM Tris-HCl at pH 7.5, 100 mM potassium chlo-
ride, 2.5 mM magnesium chloride, 1 mM DTT, 0.1 mg/mL cyclo-
heximide, 0.5% Triton X-100, 40 units/mL DNase I from NEB,
HALT protease inhibitor cocktail EDTA-free from Thermo
Scientific). The cells were allowed to swell for 10min on ice and cen-
trifuged at 16,000g for 10 min at 4°C.
Immunoblot analysis and densitometry
Transiently transfected HEK293T cells expressing SLFN14
(WT/mut)-myc/myc EV and SLFN14(WT)-GFP were lysed as
above and analyzed using densitometry after immunoblotting.
Western blot band intensity was quantified in NIS Elements version
4.00.07 as follows: The ROI selection tool was used to draw around
the largest band and the average intensity was measured. This box
was used to measure the average band intensity of other bands.
Background intensity was measured using the same ROI box moved
to 4× nonband region in the same lane as the band measured. These
values were logged to Excel; for both SLFN14 and GAPDH the av-
erage band value was then subtracted from the average background
value. To correct for minor differences in protein levels seen in the
GAPDH protein control, the band value for SLFN14 was divided by
the average band value for GAPDH.
Coimmunoprecipitation
Cell extract lysates were prepared from transiently transfected
HEK293T cells expressing SLFN14(WT)-myc, Myc EV and
SLFN14(WT/mut)-GFP or harbouring empty GFP vector as de-
scribed previously. Protein concentrations in lysates were normal-
ized using Bradford Reagent (Sigma) and absorbance was
measured in the 595 nm region using a VersaMax spectrophotom-
eter (Molecular Devices). Protein G Sepharose (PGS) (Sigma) beads
were washed three times in PBS and allowed to hydrate in pH 7.4
TBS-T (0.2 M Tris base [Sigma], 1.5 M NaCl [Sigma], 0.05%
Tween20 [Sigma[) for 30 min. Lysates were precleared by addition
of 25 µL of hydrated PGS beads for 30 min at 4°C, followed by
9000 rpm centrifugation for 15 min at 4°C. The supernatant was re-
moved and 5 µg of anti-myc antibody was added to the lysates along-
side 50 µL of hydrated PGS beads and rotated overnight at 4°C.
Beads were pelleted at 9000 rpm for 1 min at 4°C. Supernatant
was discarded and the beads washed three times in lysis buffer,
repelleting in between washes. Fifty microliters of 3× reducing sam-
ple buffer was added to the beads and boiled at 105°C for 5 min.
Whole-cell and IP lysates were analyzed by Western blot.
HEK293T ribosomal fractionation
To perform ribosomal fractionation, 100 µL of HEK293T cell extract
was diluted with 300 µL of buffer A (20 mMTris-HCl at pH 7.5, 100
mM KCl, 2.5 mM MgCl2, 1 mM DTT, 0.1 mg/mL cycloheximide)
and subjected to centrifugation through 10%–50% SDG prepared
in buffer B (20 mM Tris-HCl at pH 7.5, 100 mM KCl, 15 mM
MgCl2, 1 mM DTT, 0.1 mg/mL cycloheximide) in a Beckman
SW41 rotor at 35,000 rpm for 150 min at 4°C. After centrifugation,
200-µL fractions were collected. Ribosomal fractions were concen-
trated and analyzed by immunoblotting.
Ribosomal binding assay
SLFN14(WT)-65 kDa or SLFN14(K218E)-65 kDa proteins in the
form of eluates after Ni-NTA resin were mixed with 50 pmol 80S ri-
bosomes, reconstituted from purified 40S and 60S ribosomal sub-
units, in the presence of 1 mM AMPPNP. The reaction mixture
was subjected to centrifugation through 10%–30% SDG prepared
in buffer C (20 mM Tris-HCl at pH 7.5, 100 mM KCl, 2.5 mM
MgCl2, 1 mM DTT) in a Beckman SW55 rotor at 53,000 rpm
for 75 min at 4°C. The 80S ribosomal peak was assayed by
NuPAGE 4%–12% Bis-Tris SDS-PAGE (Invitrogen) and SimplyBlue
SafeStain (Invitrogen) staining.
RNA extraction
Total RNA extraction was performed using TRIzol reagent accord-
ing to the manufacturer’s instructions (Life Technologies). Total
RNA concentration was determined using a Nanodrop Lite spectro-
photometer (Thermo Fisher Scientific).
Denaturing agarose/formaldehyde gel electrophoresis
analysis of rRNA degradation
To study rRNA degradation in HEK293T cell extract, 1 µg of each
total RNA sample was analyzed by denaturing agarose/formalde-
hyde gel electrophoresis. RNA samples were loaded in a loading
buffer (5× = 4 mM EDTA, 0.9 M formaldehyde, 20% glycerol,
30.1% formamide, 4× FA buffer, 0.4 µg/mL bromphenol blue)
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onto 1.2% denaturing agarose/formaldehyde gel (3% formalde-
hyde) prepared in FA buffer (20 mM MOPS at pH 7.0, 5 mM
NaAc, 1 mM EDTA, 0.1 µg/mL ethidium bromide) and were re-
solved in FA buffer for 22 min at 4°C at 200 V. After electrophoresis,
gel was stained twice for 8 min each with 0.5 µg/mL ethidium bro-
mide solution in water, washed three times for 5 min each with wa-
ter and analyzed using shortwave UV (254 nm).
RNA integrity analysis on Agilent 2200
TapeStation system
After RNA isolation, total RNA was checked for the integrity of the
18S and 28S rRNAs on the Agilent 2200 TapeStation system (Agilent
Technologies). One microgram of each total RNA sample was ana-
lyzed. The Agilent software generates an electropherogram profile
and gel-like image providing a detailed visual assessment of the
quality of an RNA sample. To remove individual interpretation in
RNA integrity, the Agilent 2200 TapeStation system also provides
information about RNA quality in the form of a RIN. The RIN soft-
ware algorithm takes into account the entire electrophoretic trace
and allows for the classification of eukaryotic total RNA, based on
a numbering system from 1 to 10, with 1 being the most degraded
profile and 10 being the most intact.
qRT-PCR
To evaluate the relative SLFN14 transcript level in cells, 1 µg of iso-
lated total RNA was converted into cDNA using random hexamers
and SuperScript III kit (Invitrogen). Ten nanograms of cDNA was
subjected to real-time PCR using iQ SYBR Green Supermix kit
(Bio-Rad) with primers
SLFN14 qPCR dir 5′-GCAAAGAAGTGGTTGGATGTAAG-3′,
SLFN14 qPCR rev 5′-TCACAGCAGAAGTGGAATGTAG-3′,
GAPDH qPCR dir 5′-GGTGTGAACCATGAGAAGTATGA-3′
GAPDH qPCR rev 5′-GAGTCCTTCCACGATACCAAAG-3′,
and CFX96 Touch Real-Time PCR Detection System (Bio-Rad).
SLFN14 transcription level was normalized to GAPDH control.
SLFN14 oligomerization assay
Five micrograms of SLFN14(WT/mut)-45 kDa were analyzed by
nondenaturing NativePAGE 4%–16% Bis-Tris PAGE (Invitrogen)
and SimplyBlue SafeStain (Invitrogen) staining in the presence of
NativeMark Unstained Protein Standard (Invitrogen).
Steady-state fluorescence measurements
Fluorescence emission spectra were obtained on a Fluoromax-3
spectrophotometer (Jobin Yvon Inc., Edison, NJ). Six micrograms
of SLFN14(WT)-45 kDa or SLFN14(K218E)-45 kDa in 200µL of
buffer C were incubated at 25°C or 65°C for 10 min. Protein fluores-
cence was monitored using an excitation wavelength of 280 nm and
an emission wavelength range of 300–400 nm.
Immunocytochemistry
Dami cells (American Type Culture Collection) were plated onto
glass coverslips and transfected with SLFN14(WT/mutant)-myc as
described above. Cells were fixed in 4% PFA for 5 min, and permea-
bilized in 0.1% Triton-X-100 in PBS for 5 min. Cells were incubated
in block buffer (PBS [Invitrogen], 10% goat serum [Gibco], 5%
BSA) for 1 h. Cells were then incubated for 1 h in primary antibody
diluted in block as per manufacturer’s instructions. Cells were
washed in PBS and incubated for 1 h in secondary antibody plus
Topro-3 (Invitrogen) diluted as per manufacturer’s instructions
in block. Cells were mounted on glass slides using Hydromount
mounting media (National Diagnostics).
Immunofluorescence microscopy and analysis
All images were taken using a DM IRE2 Leica inverted microscope,
SP2 confocal system running Leica Confocal Software Version 2.61
Build 1537. Confocal imaging was performed using the 488 nm line
of an Argon-Ion laser 457–514 nM (to image AlexaFluor488 labeled
constructs) and the 568 and 633 line of the HeNe lasers (to image
AlexoFluor558 labeled constructs and TOPRO-3) with an HCX
Plan Apo Ibd.BL 63× NA 1.4, Olympus objective. Z-stack images
were taken at 10 slices per cell. Images were analyzed using NIS
Elements Software.
Colocalization between SLFN14(WT/Mut)-myc and 5.8S rRNA
was performed as follows: From average intensity projections the au-
tomated ROI tool in NIS-Elements, the entire cell volume, the cell
cytoplasm and the nucleus of each cells were selected.
Subsequently, a Pearson’s coefficient comparing SLFN14(WT/
Mut)-myc and 5.8S rRNA signals in these regions were obtained.
In order to control for random colocalization, the 5.8S RNA image
was rotated by 5°C and a Pearson’s coefficient repeated. All values
were logged to Excel (Microsoft) A Student’s Test was performed
to ascertain statistical significance between colocalization within
the various subcellular regions for wild-type of mutant SLFN14
and as a control between the rotated and nonrotated images.
Intensity measurements
Average intensity projections were created and ROIs drawn around
the entire cell volume of a bright-field image of both nontransfected
cells and cells expressing SLFN14(WT/Mut)-myc images within the
same field of view. This ROI outline was superimposed over the 5.8S
rRNA stained image and the average intensity measurement within
the ROI calculated. All values were logged to Excel (Microsoft). A
Student’s test was performed to ascertain statistical significance be-
tween 5.8S RNA staining intensity between transfected and non-
transfected cells.
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